ROLE OF SERUM S-100B PROTEIN AND MRI IN PREDICTING THE NEUROLOGICAL OUTCOME AND SEQUELAE IN NEONATES ≥ 36 WEEKS WITH BIRTH ASPHYXIA.

Abstract

A prompt diagnosis of neonatal hypoxic-ischemic encephalopathy (HIE) remains a clinical challenge. This study aimed at exploring the potential of Serum protein S100B as a biomarker for evaluating neonatal HIE in newborns with moderateto-severe hypoxic-ischemic encephalopathy. Blood samples were collected from neonates with mild, moderate, or severe HIE who were admitted to the Department of Neonatology, Madras Medical College (MMC), Chennai between September 2016 to March 2017. The plasma levels of S100 B protein were measured at different time points. Additionally, Neurodevelopmental outcomes were also studied using MRI in surviving infants (> 2 weeks). Eighty-four neonates enrolled in the study had moderate (n = 37), severe (n = 13) and mild HIE (n= 36). At birth, serum protein S100 B increased with the severity of HIE (P < .001), and remained elevated in neonates with moderate to severe HIE. Serum protein S100 B was greater up to 72 hours in moderate to severe vs mild HIE. The Elevated levels of S100B were associated with increased brain injury as studied by MRI. The study suggests S S100 B may serve as a potential biomarker for neonatal mild HIE (n=36), moderate (n=37) and severe (n=13) could be used for stratication at birth as elevated levels are correlated with the severity of HIE.